Jessica Ludwig
Family · Bonifay, FLNPI 1346589629
Payments from drug & device makers
Across 185 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$721
- AstraZeneca$395
- Lilly USA, LLC$354
- Astellas Pharma US Inc$328
- Novo Nordisk$186
- Pfizer$158
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,149100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $721 |
| AstraZeneca | 20 | $395 |
| Lilly USA, LLC | 23 | $354 |
| Astellas Pharma US Inc | 15 | $328 |
| Novo Nordisk | 10 | $186 |
| Pfizer | 8 | $158 |
| GSK | 9 | $130 |
| Dexcom, Inc. | 5 | $126 |
| Biohaven Pharmaceuticals, Inc. | 9 | $116 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $91 |
| Boehringer Ingelheim | 3 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| Novartis | 4 | $63 |
| Exact Sciences | 3 | $50 |
| Grifols USA, LLC | 2 | $47 |
| Amgen | 3 | $46 |
| IBSA Pharma Inc. | 2 | $43 |
| Corium, LLC | 1 | $30 |
| Merck | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$3,149 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $37,467 |
| MounjaroTirzepatide | 19 | $21,860 |
| FarxigaDapagliflozin Propanediol | 20 | $20,831 |
| VraylarCariprazine Hcl | 13 | $18,109 |
| JanuviaSitagliptin Phosphate | 11 | $14,858 |
| XareltoRivaroxaban | 12 | $12,005 |
| EliquisApixaban | 14 | $8,714 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,965 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,028 |
| Levothyroxine Sodium | 66 | $1,010 |
| Omeprazole | 53 | $845 |
| Celecoxib | 23 | $776 |
| Gabapentin | 60 | $762 |
| Bupropion XlBupropion Hcl | 43 | $752 |
| Nystatin | 12 | $691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $186 | $37,46728 claims |
| Lilly USA, LLCMounjaro | $354 | $21,86019 claims |
| AstraZenecaFarxiga | $395 | $20,83120 claims |
| AbbVieVraylar | $721 | $18,10913 claims |
| MerckJanuvia | $23 | $14,85811 claims |
| PfizerEliquis | $158 | $8,71414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Bonifay
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.